As expiration dates for key patents approach, the blockbuster cancer drug pembrolizumab (Keytruda) reigned as the biggest pharma moneymaker one more time, edging out the diabetes/weight-loss drug ...

The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

Our immune system is great at fighting many types of cancer, but it struggles to see prostate tumors. While new treatments have been game-changers for lung cancer and skin cancer, prostate cancer ...

Dr Fred Saad of the University of Montreal discusses the future direction of alpha emitter agents in the treatment of prostate cancer, emphasizing the logical progression of resea ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced that it has received notification from its licensing partner, Accord Healthcare, that the European Medicines Agency's (EMA) Committee for ...

CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

In this observational study, researchers aimed to assess real-world use of relugolix among prostate cancer patients.

The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...

Learn the key warning signs of prostate cancer that men often overlook. Early awareness can make all the difference.

Patients with a type of prostate cancer known as metastatic castration-sensitive prostate cancer (mCSPC), who have specific genetic mutations, were found to have improved survival by using a targeted ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...